Information Provided By:
Fly News Breaks for May 14, 2018
May 14, 2018 | 09:09 EDT
As previously reported, Jefferies analyst Johnny Kin Man Wong downgraded China Biologic Products to Hold from Buy and cut his price target on shares to $83 from $97 citing a lack of visibility ahead. In a research note to investors, the analyst said healthcare reforms are likely to impact the company more harshly than originally expected as hospitals continue to hold back from ordering despite what he feels is healthy end demand.
News For CBPO From the Last 2 Days
There are no results for your query CBPO